Ai2 Raises £1.75M

Ai2 Limited, a Manchester, UK-based company that has developed proprietary human protein-like substances which inhibit bacteria, fungi and viruses, has raised £1.75m in funding.

Backers include managers of The North West Fund for Biomedical, SPARK Impact, which injected £800k, and MTI Firms, managers of UMIP Premier Fund, which committed £950k.

The Manchester University spin-out will use the funds to continue to develop its technology.

Led by CEO Dr Jim McNairney, Ai2’s products, proprietary human protein-like substances, can be used to prevent infection on a wide range of commonly used medical devices like urinary catheters and stents as well being utilised in wound dressings and consumer products.



Join the discussion